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INTRODUCTION
Retinal vein occlusion (RVO) is an important cause of visual loss 
worldwide. It is the second-most common retinal vascular disorder, 
and epidemiologic studies reported prevalence rates of 0.7-1.6% in 
the general population(1-2). An estimated 520 new cases per 1 million 
people develop annually(3) and 15.3% of cases involve the central 
retinal vein. 
Macular edema, ischemic maculopathy, anterior and posterior 
segment neovascularization, vitreous hemorrhage, and neovascular 
glaucoma (NVG) are possible complications associated with central 
retinal vein occlusion (CRVO). The anterior segment is the main site of 
neovascularization in CRVO. The risk of development increases with 
the degree of retinal ischemia, and it is most likely to develop during 
the first 3 months after occlusion(4,5). The cumulative incidence of 
NVG in ischemic CRVO is approximately 40% over 1 year, compared 
with 10% in nonischemic eyes(6).
The Central Vein Occlusion Study (CVOS) reported that scatter 
panretinal laser photocoagulation (PRP) is recommended promptly 
after the development of neovascularization over 2 h or more in the 
iris or any angle neovascularization(7).
Recent prospective, randomized, controlled trials evaluated 
intravitreally injected drugs for treating CRVO and tried to define 
treatment strategies for macular edema secondary to CRVO.
Steroids reduce vascular permeability and stabilize the blood-re-
tina barrier(8). The mechanism involves inhibition of inflammatory me-
diators and vascular permeability factors such as vascular endothelial 
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ABSTRACT
Purpose: To analyze the effects of injections of intravitreal triamcinolone aceto-
nide (IVTA) and intravitreal bevacizumab (IVB) on the incidence rates of anterior 
segment neovascularization (ASN) and neovascular glaucoma (NVG) in patients 
with macular edema secondary to central retinal vein occlusion (CRVO). 
Methods: In this prospective, randomized, double-masked, sham-controlled study, 
35 patients with macular edema following CRVO were randomized to intravitreal 
bevacizumab, intravitreal triamcinolone acetonide, or sham injections during the 
first 6 months of the study. The primary outcome was the incidence rate of ASN 
at month 6. The secondary outcomes were the mean changes from baseline in 
best-corrected visual acuity (BCVA) and central foveal thickness (CFT) on optical 
coherence tomography over time to month 12. 
Results: ASN developed in 8 (22.86%) eyes, including 5 (62.50%) eyes in the sham 
group and 3 (37.50%) eyes in the IVTA group, during 12 months of fol low-up 
(p=0.009). BCVA differed significantly (p<0.05) among the groups only at month 1. 
CFT did not differ significantly (p<0.05) among the groups over 12 months. NVG 
required surgery and developed in one eye despite laser treatment. 
Conclusion: Early treatment with intravitreal antivascular endothelial growth 
factor therapy decreases the rates of ASN and NVG after CRVO.
Keywords: Neovascularization; Pathologic; Bevacizumab; Retinal vein occlusion; 
Macular edema; Glaucoma; Neovascular
RESUMO
Objetivo: Analisar as taxas de incidência de neovascularização do segmento anterior 
(NSA) e de glaucoma neovascular (GNV), em pacientes com edema macular secundário 
a oclusão de veia central da retina (OVCR), em tratamento com injeções intravítreas 
de triamcinolona (IVTA) ou bevacizumab (IVB). 
Métodos: Neste estudo prospectivo, randomizado, duplo mascarado e sham con-
trolado, 35 pacientes com edema macular secundário a OVCR foram randomizados para 
IVB, IVTA ou para o grupo controle (sham), durante os 6 primeiros meses do estudo. O 
desfecho primário foi a taxa de incidência de NSA no mês 6. Os desfechos secundários 
foram alterações médias da acuidade visual corrigida (BCVA) e espessura foveal 
central (EFC) ao exame de tomografia de coerência óptica, até o mês 12. 
Resultados: NSA ocorreu em oito (22,86%) olhos, cinco (62,50%) olhos no grupo sham 
e três (37,50%) olhos no grupo tratado com injeções intravítreas de Triamcinolona, 
Não houve nenhum caso com NSA no grupo tratado com bevacizumab durante 12 
meses de acompanhamento (p=0,009). A BCVA apresentou diferença estatisticamente 
significante (p<0,05) entre os grupos, somente no mês 1. A EFC não apresentou dife-
renças estatisticamente significantes (p<0,05) entre os grupos ao longo dos 12 meses. 
GNV ocorreu em um olho apesar do tratamento com laser e este paciente necessitou 
de intervenção cirúrgica. 
Conclusão: O tratamento precoce com injeções intravítreas de Anti VEGF podem 
diminuir as taxas de neovascularização do segmento anterior e glaucoma neovascular 
após oclusão de veia central da retina. 
Descritores: Neovascularização patológica; Bevacizumab; Oclusão da veia retiniana; 
Edema macular; Glaucoma neovascular
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growth factor (VEGF); thus, it may prevent neovascularization(9,10). The 
SCORE study compared the efficacy and safety of two doses (1 and 
4 mg) of intravitreal triamcinolone acetonide (IVTA) for the treatment 
of macular edema after CRVO in 272 eyes(11). The study reported 
improved BCVA in 27% of eyes treated with 1 mg of IVTA and fewer 
ocular adverse events in this group. Neovascularization occurred in 
9.8% of eyes treated with 1 mg of IVTA and 4.4% in those treated at 
a dose of 4 mg. Implantation of sustained corticosteroid delivery 
devices resulted in improved best-corrected visual acuity (BCVA) in 
other studies(12).
VEGF plays a key role in the pathophysiology of CRVO and its com-
plications. Several studies proposed treatment with the anti-VEGF 
drugs bevacizumab (Avastin, Genentech Inc., South San Francisco, 
CA), ranibizumab (Lucentis, Genentech Inc.), and aflibercept (Eylea, 
Regeneron Pharmaceuticals, Tarrytown, NY). 
The CRUISE study illustrated that patients treated with monthly 
intravitreal ranibizumab (0.3 or 0.5 mg) achieved better results than 
controls(13). The improved BCVA was maintained at the 12-month 
endpoint. 
The HORIZON trial followed the same patients who enrolled in 
the CRUISE study during the second year. At the end of 24 months, 
BCVA did not differ significantly among the three groups (0.3 mg, 
0.5 mg, and sham)(14).
Bevacizumab is an anti-VEGF drug used to manage retinal vas-
cular disorders such as age-related macular degeneration, diabetic 
ede ma, and retinal vein occlusions(15-18). Several retrospective and 
prospective studies reported decreased retinal thickness and impro-
ved BCVA after intravitreal injections of the drug(19,20). 
Although most recent studies suggested the therapeutic bene-
fits of intravitreal steroids and anti-VEGF for treating macular edema 
secondary to CRVO, none focused on the effects of such treatments 
for preventing anterior segment neovascularization (ASN) and NVG 
as a primary endpoint.
The purpose of the this prospective study was to analyze the 
effects of intravitreal bevacizumab (IVB) injections compared with 
IVTA or sham injections for preventing ASN and NVG in patients with 
macular edema due to CRVO. 
METHODS
Study deSign
This 12-month randomized, double-masked, sham-controlled 
study was designed to evaluate the incidence rates of ASN and NVG 
in three groups treated for macular edema secondary to CRVO.
The study included a 28-day screening period, a 6-month treat-
ment period (baseline to month 6) in which patients received monthly 
injections, and an additional 6-month, open-label PRN treatment 
period (month 6 to final study visit).
The study was conducted according to the tenets of the Decla-
ration of Helsinki and federal laws. All patients were informed about 
the purpose of the study, and they provided informed consent. The 
ethics committee of our institution approved the study. The primary 
outcome was the presence of ASN in the study eye, as determined by 
ophthalmologic examination at the 6-month follow-up visit. 
Screening and eligibility
The primary investigator (LFAL) determined patient eligibility at 
the Retina Division of the Department of Ophthalmology, Federal 
University of São Paulo, using the criteria in table 1. 
During the screening visit, after providing informed consent, all 
participants provided a complete medical history and underwent an 
ophthalmologic examination that included measurements of BCVA 
using a Snellen chart, slit-lamp examination, gonioscopy, measure-
ment of intraocular pressure (IOP), pupillary reflex, binocular fun dus 
examination, optical coherence tomography (SD-OCT) (Spectralis 
OCT, Heidelberg Engineering, Heidelberg, Germany), and wide-angle 
fluorescein angiography (FA) (HRA, Heidelberg Engineering).
randomization
If the physician investigator judged a patient eligible for partici-
pation in the study, then he or she was randomized to one of three 
treatment groups as follows (Figure 1): group 1, sham injections; 
group 2, 1.25-mg IVB injections; and group 3, 1-mg IVTA injections.
The patients in groups 1 and 2 received monthly sham and 
1.25-mg IVB injections, respectively, at baseline and months 1, 2, 3, 
Table 1. Inclusion and exclusion criteria
Inclusion criteria*
≥18 years of age with macular edema secondary to CRVO and less than 90 days since symptoms appeared 
BCVA ≤20/40 according to the Snellen chart 
Central foveal thickness ≥250 μm according to a central 1-mm diameter circle with a Spectralis OCT (Heidelberg Engineering, Heidelberg, Germany)
Exclusion criteria*
Any iris or angle neovascularization evident on slit lamp or gonioscopy examination without pupillary dilation
Presence of macular edema due to a cause other than CRVO
Prior episode of RVO
IOP ≥25 mmHg, open-angle glaucoma (either primary open-angle glaucoma or other cause), prior steroid-induced IOP elevation, or pseudoexfoliation
Evidence on examination of any diabetic retinopathy
History or presence of wet or dry AMD
Any previous treatment for macular edema
Previous panretinal scatter photocoagulation or sector laser photocoagulation
Prior anti-VEGF treatment 
Any ocular surgery within 6 months before baseline
Prior pars plana vitrectomy
Intra or periocular acute infection 
*= pertains to the study eye, except where noted otherwise.
CRVO= central retinal vein occlusion; BCVA= best-corrected visual acuity; BRVO= branch retinal vein occlusion; RVO= retinal vein occlusion; IOP= intraocular pressure; AMD= age-related 
macular degeneration; VEGF= vascular endothelial growth factor.
CRVO was defined as an eye that had retinal hemorrhage or other biomicroscopic evidence of RVO (e.g., telangiectatic capillary bed) and a dilated (or previously dilated) venous system 
in ≥3 quadrants of the retina drained by the affected vein.
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4, and 5. The patients in group 3 received IVTA injections at baseline 
and month 4; at months 1, 2, 3, and 5, the eyes of patients rando-
mized to group 3 received sham injections. Moreover, for patient 
ran domization, a computer-generated randomization table was 
created (Stata v11, StataCorp, College Station, TX). Participants were 
randomized 1:1:1 to treatment groups with block sizes of three and 
six. An investigator not otherwise involved in the trial performed all 
randomization processes.
One eye of each patient was included in the study. If both eyes 
were eligible, the eye with the worse BCVA at screening was selected. 
Patients and evaluating physicians were masked to treatment during 
the first 6 months of the study. The physician who administered 
the injections (LFAL) did not perform examinations or outcome 
assessments, and he had knowledge about the drug administered or 
sham injection at the time of injection. 
Study viSitS and aSSeSSmentS
During the 6-month follow-up period, study visits occurred on 
day 0 (baseline) and months 1, 2, 3, 4, 5, and 6. During the monthly 
PRN treatment period, patients were eligible to receive monthly 
1.25-mg IVB injections if they had BCVA in the study eye of 20/40 or 
worse according to the Snellen chart and/or CFT of 250 μm or more 
according to SD-OCT. The patients continued monthly follow-up 
(months 7, 8, 9, 10, and 11 and the final study visit). At each visit, the 
recorded patient data included BCVA measured using a Snellen chart, 
slit-lamp examination, and gonioscopy; IOP measured via Goldmann 
tonometry, binocular fundus examination, and SD-OCT assessment 
of CFT. Wide-angle FA was performed at baseline and visits 6 and 12. 
Eyes with clinical findings of retinal ischemia (VA<20/200, relative 
afferent pupillary defect [APD], and cotton wool spots) were evalua-
ted and correlated with the development of ASN.
The FA findings were classified as ischemic when more than 10 
disc areas of retinal capillary nonperfusion were present and perfused 
(nonischemic) while fewer than 10 disc areas of nonperfusion were 
present(5). The perfusion status of FA was considered indeterminate 
when intraretinal hemorrhage prevented visualization of fluorescein 
in the retinal capillaries during the experiment. 
At each visit, the patients provided a medical history, the medi-
cation was reviewed, and safety was assessed. Any new sign, symp-
tom, illness, or worsening of any preexisting medical condition was 
recorded as an adverse event (AE). An AE was considered as a serious 
AE (SAE) when it resulted in death or when it was life-threatening, it 
required prolonged hospitalization, it caused persistent or significant 
disability, it was a congenital anomaly/birth defect, or it was consi-
dered a significant medical event by the investigator. Furthermore, 
patients who discontinued the study before the month 12 visit were 
CRVO=central retinal vein occlusion. 
Figure 1. Study design. Eligible patients were randomized 1:1:1 to receive monthly sham, 1.25-mg intravitreal bevacizumab (IVB), or 1-mg intravitreal triamcinolone acetonide (IVTA) 
injections during the 6-month treatment period. During the monthly pro ra nata (PRN) treatment observation period, patients were eligible to receive monthly intraocular 1.25-mg 
IVB injections if they had a Snellen equivalent best-corrected visual acuity of 20/40 or worse according to the Snellen chart or central foveal thickness of 250 μm or more according 
based on spectral-domain optical coherence tomography. 
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encouraged to return for an early final study visit 30 days after their 
last injection or analysis. If ASN was detected at any time in the study, 
the patient was referred for scatter PRP according to recent recom-
mendations. If NVG was detected despite PRP, patients were referred 
to the glaucoma sector for follow-up and treatment. 
intraocular injectionS
The procedure for drug administration at the ophthalmic surgical 
center of the Federal University of São Paulo was as described fur-
ther. Topical anesthetic drops were administered, and a lid speculum 
was used. A 5% povidone iodine drop was instilled as prophylaxis 
against infection 5 min before the procedure. A 30-gauge needle 
was inserted through the pars plana, and 0.05 ml of bevacizumab 
(OPHTHALMOS® 25 mg/ml São Paulo, Brazil) or 0.025 ml of triamci-
nolone acetonide (OPHTAAC® 40 mg/ml OPHTHALMOS São Paulo, 
Brazil) was injected(13,21). The procedure for administering sham injec-
tions was similar to that for the IVB and IVTA injections, except that the 
hub of a syringe without a needle was placed against the injection 
site and the syringe plunger was depressed to mimic an injection. The 
ability to count fingers with the study eye was assessed 1 min after 
the injection. No topical antibiotics were prescribed postoperatively 
for any patient. An additional visit within 5 days after each injection 
was scheduled as a postoperative evaluation.
outcome meaSureS
The primary outcome measure was the incidence of ASN at month 
6. The secondary outcomes included the mean changes from baseline 
in BCVA and CFT over time to month 12. The safety outcomes included 
the incidence and severity of ocular, nonocular, and systemic AEs.
StatiStical analySiS
Data were analyzed and expressed as means and standard devia-
tions or frequencies (%). Comparisons of continuous and categorical 
variables among the treatment groups were performed using the 
Kruskal-Wallis test and Fisher’s exact test, respectively. Post-hoc analy-
ses were performed using the Bonferroni test. p<0.05 was considered 
statistically significant. All analyses were performed using Stata v11.
RESULTS
baSeline demographicS and ocular characteriSticS 
Between September 2013 and May 2015, 35 eyes of 35 patients 
in the Retina Sector of the Federal University of São Paulo, Brazil, were 
randomized, that is, 10, 14, and 11 eyes to the sham, IVB, and IVTA 
groups, respectively. Thirteen patients completed the screening visit, 
but they were excluded as follows: seven had glaucoma; three did 
not provide informed consent; two were excluded because of social 
issues; and one was excluded because ASN was detected during the 
screening visit. The patient demographic data were similar across the 
treatment groups (Table 2). The baseline ocular characteristics were 
also similar across treatment groups excluding APD (p<0.05). 
The mean patient age was 59.48 years (range, 31-89 years), and 60% 
of patients were men. The average time for symptom development was 
31.08 days (range, 3-85 days). The mean baseline BCVA (logarithm of 
the minimum angle of resolution [logMAR]) of the study eye was 1.43 
(±0.53) (Snellen equivalent, 20/538), and 27 eyes (77.14%) had BCVA 
of less than 20/200. 
The baseline biomicroscopic examination illustrated that 34 (97.14%) 
eyes were phakic, and one (2.86%) was pseudophakic. Fifteen (42.86%) 
eyes had an APD. The baseline funduscopic examination indicated 
that 21 (60%) eyes had cotton-wool spots, and the mean CFT was 
754.51 μm (range, 252-1146 μm).
More than 10 disc areas of retinal capillary nonperfusion were 
present on the baseline FA images in 12 (34.29%) eyes. Five, four, and 
three of these eyes were randomized to sham, IVTA, and IVB treat-
ment, respectively. The other 11 eyes had less than 10 disc areas of 
retinal capillary nonperfusion, and in 11 eyes, the area of nonperfu-
sion was undetermined (p=0.357).
primary endpoint
Eight (22.86%) eyes had ASN. Five eyes randomized to sham 
treatment (50%) and three eyes randomized to 1 mg IVTA (27.27%) 
developed ASN. No eyes randomized to IVB developed ASN in the iris 
and/or angle during 12 months of follow-up (p=0.009).
The overall mean time for development of ASN was 59.75 ± 42.79 
days, that is, 65.6 ± 54.22 days in the sham group and 50 ± 17.32 days 
in the IVTA group (p>0.05).
We also analyzed the presence of clinically diagnosed retinal 
ischemia (BCVA<20/200, APD, and cotton-wool spots). At baseline, 
10 eyes presented clinical findings suggestive of retinal ischemia. Of 
these, five were randomized to the IVB group, and none developed 
ASN during the follow-up period. The remaining five eyes with ische-
mia developed ASN, three and two of which were randomized to the 
sham (p=0.17) and IVTA groups (p=0.056). Two patients randomized 
to sham treatment did not exhibit baseline retinal ischemia, but ASN 
developed during the follow-up period. 
Twelve eyes had more than 10 disc areas of retinal capillary non-
perfusion on the baseline FA images. Of these, eight (66.67%) develo-
ped ASN (five eyes in the sham group [p=0.02] and three eyes in the 
triamcinolone group [p=0.14]). Four eyes displayed the angiographic 
criteria of ischemia, but ASN did not develop (three eyes randomized 
to IVB and one eye randomized to IVTA) (Table 3). 
Functional outcomeS at month 12
At months 6 and 12, the mean logMAR BCVA levels were 0.96 ± 
0.67 (p=0.41) and 0.99 ± 0.53 (p=0.44), respectively. The mean change 
in BCVA during the first 12 months in the groups is shown in figure 2. 
BCVA differed significantly (p<0.05) among the groups only at month 
1. Macular ischemia was observed in 13 eyes, including four (40%), 
five (45.45%), and four (28.57%) eyes randomized to sham, IVTA, and 
IVB treatment (p=0.84), respectively.
anatomic outcomeS at month 12
At months 6 and 12, the mean CFTs were 345.4 ± 182.87 (p=0.39) 
and 346.17 ± 195.92 (p=0.35), respectively. The mean changes in CFT 
on SD-OCT during the first 12 months in the groups are shown in 
figure 3. CFT did not differ significantly among the groups during 
this period.
Safety outcomes at month 12
Seven (20%) eyes developed or exhibited worsening of cataracts 
(p=0.31). Ten patients required topical antiglaucomatous drops for 
increased IOP, none of whom had uncontrolled IOP. The differences 
among the groups did not reach significance (p=0.41). One patient 
discontinued follow-up 3 months after inferior paresis that required 
hospitalization. The patient was diagnosed with Miller Fisher syndro-
me. Another patient with cardiomyopathy related to Chagas disease 
required pacemaker implantation during follow-up.
All patients with ANS were referred for scatter PRP. NVG develo-
ped in one patient despite laser treatment, and surgery was needed 
to control IOP.
DISCUSSION
CRVO is an important cause of irreversible visual loss worldwide. 
The natural disease history has a poor prognosis that is proportional 
to the degree of retinal ischemia(5). Macular edema is an important 
cause of visual loss in these patients, and the benefits of intravitreal 
injections have been reported(11-14). Other possible complications 
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Table 2. Patient demographics and baseline ocular characteristics
Sham (n=10)
Bevacizumab 
1.25 mg (n=14)
Triamcinolone acetonide 
1 mg (n=11) 
Among-group 
p value*
Age (years)
Mean (SD) 55.6 (14.41) 61.86 (12.62) 60 (12.63) 0.450
Range 31-83 37-89 45-80 
Gender, n (%) 1.000
Male 6 (60%) 9 (64.29%) 7 (63.64%)
Female 4 (40%) 5 (35.71%) 4 (36.36%)
Race, **n (%) 0.460
White 6 (60%) 7 (50.00%) 9 (81.82%)
Black 2 (20%) 4 (28.57%) 2 (18.18%)
Asiatic 1 (10%) 0 0 
Other 1 (10%) 3 (21.43%) 0 
Time of symptoms 0.482
Mean (SD) 31.9 (18.60) 25.42 (22.07) 37.54 (30.11) 
Range 4-60 3-60 3-85
BCVA (logMAR) 0.275
Mean (SD) 1.64 (0.44) 1.32 (0.53) 1.40 (0.62)
Range 0.9-2.2 0.3-1.79 0.5-2.2
VA<20/200, n (%) 9 (90%) 11 (78.57%) 7 (63.64%) 0.418
Cotton wool spots, n (%) 6 (60%) 08 (57.14%) 7 (63.64%) 1.000
Afferent pupillary defect, n (%) 6 (60%) 07 (50.00%) 2 (20.00%) 0.029
Lens status, n (%) 1.000
Phakic 10 (100%) 13 (92.86%) 11 (100%) 
Pseudophakic 0 01 (07.14%) 0
>10 DA of capillary non-perfusion, n (%) 0.357
Yes 5 (55.56%) 3 (21.43%) 4 (36.36%)
No 3 (33.33%) 4 (28.57%) 4 (36.36%)
Undetermined 1 (11.11%)  7 (50.00%) 3 (27.27%)
CFT (SD-OCT), µm 0.500
Mean (SD) 774.87 (276.85) 706 (261.93) 813 (152.90) 
Range 252-1059 262-1146 555-999
*= P-values less than 0.05 were considered statistically significant; **= multiracial patients were counted in each race category that they indicated.
SD=standard deviation; BCVA=best correct visual acuity; VA=visual acuity; CFT=central foveal thickness; SD-OCT=spectral domain optical coherence tomography.
Table 3. Primary outcome 
 
Sham (n=8)
Bevacizumab 1.25 mg 
(n=11)
Triamcinolone acetonide 
1 mg (n=9) 
Among-group 
p value*
Clinical findings of retinal ischemia**
(VA <20/200 + cotton-wool spots + afferent pupillary defect)
n 3 5 2
ASN, n (%) 3 (100) 0 2 (100)
P 0.17 0.056
Fluorescein angiography**
(>10 DA of capillary non-perfusion)
n 5 3 4
ASN, n (%) 5 (100) 0 3 (075)
P 0.02 0.140
Total ASN, n (%) 5 (50)  0 3 (27.27) 0.009
*= P-values less than 0.05 were considered statistically significant; **= at the baseline visit.
VA= visual acuity; DA= disk area; ASN= anterior segment neovascularization.
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Figure 3. Mean change from the baseline central foveal thickness (CFT) over time to 
month 12. CFT did not differ significantly among the groups over the 12 months. 
Figure 2. Mean change from baseline best-corrected visual acuity (BCVA) in the study 
over time to month 12. Statistically significant BCVA logarithm of the minimum angle of 
resolution (logMAR) (*p<0.05) difference was found at Month enter groups.
related to CRVO are ASN and NVG. The cumulative incidence of NVG 
is 40% in ischemic CRVO and 10% in nonischemic CRVO(6). Despite 
the fact that many studies reported the benefits of intravitreal medi-
cations for improving BCVA and macular edema, there is little infor-
mation about the impact of treatment on the natural history of ASN. 
This study was a prospective analysis of different treatments for 
macular edema after CRVO with focus on preventing ASN and NVG.
Differentiating between ischemic and nonischemic CRVO may 
be challenging in the early stages. Clinical features such as initial 
BCVA worse than 20/200, APD, and cotton-wool spots are suggestive 
of ischemic CRVO and can predict prognosis(3,5,22-25). The presence 
of extensive nonperfused capillary areas in the FA images is a good 
indicator of retinal ischemia(5,6), but this can be difficult to assess while 
setting CRVO with substantial intraretinal hemorrhages. Although 
electroretinogram (ERG) is a good indicator of retinal ischemia in 
CRVO(23,26-28) and is predictive of iris neovascularization(29,30), it is ex-
pensive and not always available in daily clinical practice. Considering 
the difficulty of performing ERG, we correlated the clinical data that 
suggested ischemic CRVO with the development of ASN. Thus, it is 
possible to assess which patient groups may benefit from each ma-
cular edema treatment to prevent this complication. 
In this study, ASN developed in eight (22.86%) patients. Ramezani 
et al. reported an incidence as high as 50% at 6 months after CRVO in 
a study in which the CRVO subtype was unclassified(30). In the CVOS, 
which considered eyes initially categorized as nonperfused or inde-
terminate, 35% of eyes developed ASN, compared with 10% of eyes 
initially categorized as perfused(5).
Five (62.5%) eyes that developed ASN were randomized to sham 
treatment, and three (37.5%) eyes were randomized to the IVTA 
group. No eyes in the IVB group developed ASN during the first 6 
months of follow-up (p=0.009).
In this study, ASN developed after an average of 59.75 ± 42.79 
(65.6 ± 54.22 days in the sham group; and 50 ± 17.32 days in the 
triam cinolone group).
Twelve patients had baseline FA images classified as ischemic. 
Among these patients, five, four, and three eyes were randomized to 
sham, IVTA, and IVB treatment, the last of which was the only group 
with an ischemic angiographic pattern that did lead to the deve-
lopment of ASN. 
The CRUISE study reported iris neovascularization in only 12 of 
390 eyes and NVG in two eyes. Only three patients treated with rani-
bizumab in that study developed iris neovascularization, and none 
developed NVG; however, the study excluded patients with APD and 
included patients with BCVAs ranging from 20/40 to 20/320. In this 
study, BCVA and APD were not the exclusion criteria, and our sample 
probably included patients with more severe retinal ischemia com-
pared to the CRUISE study.
The functional and anatomic outcomes in this study were worse 
than the SCORE and CRUISE results. BCVA in patients treated with 
anti-VEGF injections was significantly (p<0.05) better than that in 
the other groups only at month 1. CFT measured on SD-OCT images 
in these patients was not significantly better than that in the other 
groups. These results are probably related to the small sample size 
and the inclusion of patients with a worse prognosis compared to 
patients in other trials.
At the end of the 12-month follow-up period, we found similar 
ocular adverse events (cataract and ocular hypertension) rates com-
pared with previous studies(11). Endophthalmitis did not develop 
during the study. No SAEs reported were related with the use of the 
study medications. 
Although this was a prospective, randomized, sham-controlled 
study, our study had limitations, including the small sample size in 
each group, which might have compromised the statistical power 
to detect differences.
CONCLUSION
In conclusion, early treatment with IVB decreases the rates of 
ASN and NVG after CRVO in eyes with clinical signs suggestive of 
ischemia. Multicenter studies with larger samples of patients should 
be performed to confirm these findings. 
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